Vera Bradley, Inc., together with its subsidiaries, designs and manufactures women's handbags, luggage and travel items, fashion and home accessories, and gifts in the United States. It operates in three segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The company offers bag products, such as backpacks, totes, crossbodies, lunch bags, satchels, clutches, and baby bags; accessories, including ID holders, lanyards, wallets, wristlets, eyewear, scarves, various technology accessories, and hair accessories, as well as bracelets, rings, necklaces, tees, and hoodies under the Pura Vida brand. It also provides travel products comprising rolling luggage, cosmetics, travel and packing accessories, and travel bags, which include duffel and weekend bags; home products, such as textiles, throw blankets, beach towels, bedding, mugs, and tumblers; sleepwear, footwear, outerwear, socks, and tops under the Vera Bradley brand; and stationery, licensing, freight, merchandising, and gift card breakage services. The company sells its Vera Bradley branded products through its full-line and outlet stores in the United States; e-commerce sites, such as verabradley.com, outlet.verabradley.com, and international.verabradley.com; and its annual outlet sale in Fort Wayne, Indiana, as well as through specialty retail locations, department stores, national accounts, third party e-commerce sites, third-party inventory liquidators, and through licensing agreements. It sells its Pura Vida branded products through wholesale retailers and department stores; and its Pura Vida website, www.puravidabracelets.com. Vera Bradley, Inc. was founded in 1982 and is headquartered in Roanoke, Indiana.

Vera Bradley, Inc.

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Savara, with a price target of $10.00. Brisebois cov...

LifeSci Capital Remains a Buy on Savara (SVRA)

In a report released today, Benjamin Burnett from Wells Fargo maintained a Buy rating on Savara, with a price target of $9.00. According to TipRank...

Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA)

Roth MKM analyst Jonathan Aschoff maintained a Buy rating on Zevra Therapeutics today and set a price target of $21.00. According to TipRanks, Asch...

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Zevra Therapeutics, with a price target of $20.00. Ku...

Canaccord Genuity Remains a Buy on Zevra Therapeutics (ZVRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NewAmsterdam Pharma Company (NAMS) and Zevra Therape...

Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Zevra Therapeutics (ZVRA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zevra Therapeutics (ZVRA), Roche Holding AG (RHHVF) and Quest Dia...

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Roche Holding AG (OtherRHHVF) and Quest Diagnostics (DGX)

Virax Biolabs Group Ltd. Class A ( ($VRAX) ) has issued an announcement. Virax Biolabs Group Limited, a Nasdaq-listed biotechnology company focused...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRA	$3.27	0.00%	73.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRA	$3.27	0%	73.58K
3
4
5
6

VRA

Get Vera Bradley, Inc. Data in Excel

Get Vera Bradley, Inc. Data in Excel